RHEUMATOID ARTHRITIS DIAGNOSTIC TESTS MARKET ANALYSIS

Rheumatoid Arthritis Diagnostic Tests Market,Rheumatoid Arthritis Diagnostic Tests Market, By Test Type (Serology Test (Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, Other Tests), Monitoring RA Treatment Efficiency Tests (Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), Creatinine Test)), By End User (Diagnostic Laboratories, Private Laboratories, Public Laboratories, Ambulatory Surgical Centers), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jun 2023
Code : CMI3716
Pages :165
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Leading Companies

Global Rheumatoid Arthritis Diagnostic Tests Market - Key Players

Major players operating in the global rheumatoid arthritis diagnostic tests market include Abbott Diagnostics (Abbott Laboratories), Labcorp ,Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, and Augurex Life Sciences Corp., Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB, and Thermo Fisher Scientific Inc.

Global Rheumatoid Arthritis Diagnostic Tests Market: Key Trends

Application of biomarker test for diagnosing rheumatoid arthritis

Application of biomarker test for diagnosing rheumatoid arthritis is at an early stage of development. Major players in the market are focused on adopting partnership strategies to expand their product portfolio. Presently, there is no biochemical test available for the diagnosis of RA. However, Rheumatoid Factor (RF) and Anti–Cyclic Citrullinated Peptide (anti–CCP) antibodies test require more refinement to improve their clinical utility. For instance, in March 2020, WorldCare Clinical, LLC, an independent CRO offering imaging in clinical trials partnesred with Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals to offer imaging service following FDA approval of Navidea’s RA diagnostic.